Cardiovascular & Hematological Disorders-Drug Targets最新文献

筛选

英文中文

In silico Evaluation of ACE2 Inhibition by Prunus armeniaca L. and in vivo Toxicity Study 杨梅抑制 ACE2 的硅学评估和体内毒性研究

Cardiovascular & Hematological Disorders-Drug Targets Pub Date : 2023-12-14 DOI: 10.2174/011871529x265182231211103724

Ismail Bouadid, Soumia Moujane, Mourad Akdad, Moualij Benaissa, M. Eddouks

引用次数: 0

Therapeutic Drug Monitoring of Voriconazole in Children with Hematologic Malignancy and Invasive Fungal Infections: An RCT Study from a Tertiary Care Centre in India 血液恶性肿瘤和侵袭性真菌感染患儿中伏立康唑的治疗药物监测：印度一家三级医疗中心的 RCT 研究

Cardiovascular & Hematological Disorders-Drug Targets Pub Date : 2023-11-21 DOI: 10.2174/011871529x245299231102055046

Neha Sharad, Gagandeep Singh, I. Xess, Reshu Agarwal, Tulika Seth, K. H Reeta, Sweta Kothari

{"title":"Therapeutic Drug Monitoring of Voriconazole in Children with Hematologic Malignancy and Invasive Fungal Infections: An RCT Study from a Tertiary Care Centre in India","authors":"Neha Sharad, Gagandeep Singh, I. Xess, Reshu Agarwal, Tulika Seth, K. H Reeta, Sweta Kothari","doi":"10.2174/011871529x245299231102055046","DOIUrl":"https://doi.org/10.2174/011871529x245299231102055046","url":null,"abstract":"Voriconazole is a triazole anti-fungal with non-linear kinetics and a narrow therapeutic range. The objective of our study was to monitor the voriconazole serum levels in children with hematological malignancy and clinically suspected invasive fungal infections. The study was a prospective, randomized controlled trial conducted from June 2016 to December 2017. All children who had haematologic malignancies with clinically suspected invasive fungal infections and received voriconazole as the only anti-fungal were included in the study. The children were randomly allotted into two groups; one was the group that underwent TDM, and the other, TDM, was not done. Bioassay was the method employed for TDM. The trough levels were evaluated on a sample obtained on the fifth day of starting the drug. The institute's ethics committee approved the study. A total of 30 children were included in the study: 15 in the TDM group and 15 in the non-TDM group. The most common underlying malignancy was AML. Neutropenia due to chemotherapy sessions was these patients' most common risk factor. A favorable outcome was seen in 13/15 (86.7%) in the TDM group and 11/15 in the non-TDM group (73.3%). Only five out of 15 (33.3%) children had voriconazole serum levels within the therapeutic range. Alterations in dose had to be done in the remaining to achieve the recommended serum levels. Thus, we recommend TDM for all children of hematologic malignancy receiving voriconazole for better management. Our findings also revealed that children with AML had lower than recommended levels of voriconazole on TDM evaluation, whereas those with ALL had normal to elevated levels of voriconazole.","PeriodicalId":504023,"journal":{"name":"Cardiovascular & Hematological Disorders-Drug Targets","volume":"95 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139254859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular &amp; Hematological Disorders-Drug Targets最新文献

Cardiovascular & Hematological Disorders-Drug Targets最新文献